76 related articles for article (PubMed ID: 18476795)
1. Intralesional therapy for advanced melanoma: promise and limitation.
Agarwala SS
Curr Opin Oncol; 2015 Mar; 27(2):151-6. PubMed ID: 25629369
[TBL] [Abstract][Full Text] [Related]
2. The immune-related role of beta-2-microglobulin in melanoma.
Wang C; Wang Z; Yao T; Zhou J; Wang Z
Front Oncol; 2022; 12():944722. PubMed ID: 36046045
[TBL] [Abstract][Full Text] [Related]
3. Vaccine Therapies for Cancer: Then and Now.
Morse MA; Gwin WR; Mitchell DA
Target Oncol; 2021 Mar; 16(2):121-152. PubMed ID: 33512679
[TBL] [Abstract][Full Text] [Related]
4. The role for chemotherapy in the modern management of melanoma.
Gupta A; Gomes F; Lorigan P
Melanoma Manag; 2017 May; 4(2):125-136. PubMed ID: 30190915
[TBL] [Abstract][Full Text] [Related]
5. The role of chemotherapy in the modern management of melanoma.
Lee RJ; Ul-Ain-Tariq N; Fusi A; Bowyer S; Lorigan P
Melanoma Manag; 2014 Nov; 1(2):173-184. PubMed ID: 30190822
[TBL] [Abstract][Full Text] [Related]
6. Nanocarrier-based immunotherapy in cancer management and research.
Singh MS; Bhaskar S
Immunotargets Ther; 2014; 3():121-34. PubMed ID: 27471704
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in the management of melanoma: current status.
Alston D; Brewer JD
Immunotargets Ther; 2013; 2():1-10. PubMed ID: 27471683
[TBL] [Abstract][Full Text] [Related]
8. Developments in Intralesional Therapy for Metastatic Melanoma.
Sloot S; Rashid OM; Sarnaik AA; Zager JS
Cancer Control; 2016 Jan; 23(1):12-20. PubMed ID: 27009452
[TBL] [Abstract][Full Text] [Related]
9. Immunological monitoring of anticancer vaccines in clinical trials.
Ogi C; Aruga A
Oncoimmunology; 2013 Aug; 2(8):e26012. PubMed ID: 24083085
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of therapeutic cancer vaccines.
Ogi C; Aruga A
Hum Vaccin Immunother; 2013 May; 9(5):1049-57. PubMed ID: 23454867
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle delivery systems in cancer vaccines.
Krishnamachari Y; Geary SM; Lemke CD; Salem AK
Pharm Res; 2011 Feb; 28(2):215-36. PubMed ID: 20721603
[TBL] [Abstract][Full Text] [Related]
12. Immunologic therapy targeting metastatic melanoma: allovectin-7.
Chowdhery R; Gonzalez R
Immunotherapy; 2011 Jan; 3(1):17-21. PubMed ID: 21174553
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7) in patients with metastatic melanoma.
Bergen M; Chen R; Gonzalez R
Expert Opin Biol Ther; 2003 Apr; 3(2):377-84. PubMed ID: 12662150
[TBL] [Abstract][Full Text] [Related]
14. Technology evaluation: Allovectin-7, Vical.
Galanis E
Curr Opin Mol Ther; 2002 Feb; 4(1):80-7. PubMed ID: 11883699
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma.
Stopeck AT; Hersh EM; Akporiaye ET; Harris DT; Grogan T; Unger E; Warneke J; Schluter SF; Stahl S
J Clin Oncol; 1997 Jan; 15(1):341-9. PubMed ID: 8996161
[TBL] [Abstract][Full Text] [Related]
16. Allovectin-7 therapy in metastatic melanoma.
Bedikian AY; Del Vecchio M
Expert Opin Biol Ther; 2008 Jun; 8(6):839-44. PubMed ID: 18476795
[TBL] [Abstract][Full Text] [Related]
17. Velimogene aliplasmid.
Soares HP; Lutzky J
Expert Opin Biol Ther; 2010 May; 10(5):841-51. PubMed ID: 20367461
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
